Rigel Pharmaceuticals is a biotechnology company focused on the discovery and development of innovative therapies for the treatment of various diseases, particularly those with unmet medical needs
The company specializes in molecular medicine, utilizing advanced technology to create targeted treatments for conditions such as cancer and immune disorders. Through its research initiatives, Rigel aims to deliver effective solutions that improve patient outcomes and enhance the quality of life for individuals facing challenging health issues.
The intense retail focus on Anavex reflects a broader market interest in neurodegenerative therapies, especially following disappointing trial results from Cassava Sciences’ simufilam.
ST. LOUIS, Oct. 16, 2024 (GLOBE NEWSWIRE) -- Optime Care, a nationally recognized specialty pharmacy and an AscellaHealth Company, today announces an expanded arrangement with Rigel Pharmaceuticals, Inc, effective October 14, 2024, to include commercial distribution of TAVALISSE® (fostamatinib). TAVALISSE is an oral medicine that can help patients manage chronic immune thrombocytopenia (ITP) by protecting their platelets from destruction.
RIGL stock results show that Rigel Pharmaceuticals missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024.
Lately, several companies have garnered attention for various reasons, and this article aims to delve into five of them, offering insights into their recent developments.
U.S. stock futures traded slightly higher this morning. Here are some big stocks recording losses in today’s pre-market trading session. Boot Barn Holdings, Inc. (NYSEBOOT) shares dropped 15.8% to $62.99 in pre-market after the company issued weak financial guidance for Q1 and FY24.
